What’s the current market cap for Pharma Mar S.A. stock?

Pharma Mar S.A. (PHM) has a market cap of €1.2bn as of June 19, 2026.

What is the P/E ratio for Pharma Mar S.A. stock?

The price to earnings (P/E) ratio for Pharma Mar S.A. (PHM) stock is 14.98 as of June 19, 2026.

Does Pharma Mar S.A. stock pay dividends?

Yes, the Pharma Mar S.A. (PHM) stock pays dividends to shareholders. As of June 19, 2026, the dividend rate is €0.8 and the yield is 1.15%. Pharma Mar S.A. has a payout ratio of 17.33% on a trailing twelve-month basis.

When is the next Pharma Mar S.A. dividend payment date?

The next Pharma Mar S.A. (PHM) dividend payment date is unconfirmed.

What is the beta indicator for Pharma Mar S.A.?

Pharma Mar S.A. (PHM) has a beta rating of 0.37. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

Buy Pharma Mar S.A. stock | €PHM Share Price

About Pharma Mar S.A.

Pharma Mar S.A. is a biopharmaceutical company based in Madrid, Spain, specializing in the research, development, and commercialization of marine-derived drugs. The company's core focus is on oncology, where it develops and produces antitumor drugs. Its product portfolio includes compounds such as Yondelis, Aplidin, and Zepzelca, each targeting various forms of cancer. Founded in 1986, Pharma Mar is part of the pharmaceutical group Zeltia. The company leverages its unique access to marine biodiversity to create differentiated products, positioning itself distinctively within the pharmaceutical industry. Pharma Mar operates globally, with a significant foothold in both European and international markets.

Ticker

€PHM

Sector

Health

Primary listing

BME

Employees

505

Headquarters

Madrid, Spain

Website

www.pharmamar.com

Pharma Mar S.A. Metrics

BasicAdvanced

€1.2bn

14.98

€4.64

0.37

€0.80

1.15%

Bulls say / Bears say

PharmaMar reported Q1 2026 total revenues of €42.9 million, up 10% year-on-year, delivering a net profit of €1.5 million compared to a €3.9 million loss in Q1 2025, and an EBITDA of €2.7 million versus -€1.1 million a year earlier (CNMV).

At March 31 2026, PharmaMar held €168.5 million in cash and equivalents against €44.7 million in financial debt, resulting in a net cash position of €123.8 million, and Ethifinance upgraded its long-term credit rating to BBB with stable outlook (CNMV).

In fiscal 2025, PharmaMar grew sales by 26.6% to €221.4 million, expanded adjusted EBITDA to €46.1 million (margin 20.8%), and generated €43.8 million of adjusted free cash flow, reflecting robust commercial execution of Zepzelca and other assets (Cinco Días).

PharmaMar’s portfolio remains concentrated, with Zepzelca accounting for the majority of recurring revenue and regulatory or commercial setbacks in this single asset could materially impact future earnings (Cinco Días).

The pivotal Phase III SaLuDo trial of lurbinectedina in leiomyosarcoma is still recruiting and is only expected to complete enrollment in Q2 2026, exposing PharmaMar to clinical and timing risks before potential future approvals (CNMV).

Royalties in Q1 2026 included €13.3 million of estimated royalties from Jazz Pharmaceuticals for Zepzelca in the US, which will be subject to reconciliation and possible downward adjustments in subsequent quarters, introducing earnings volatility (CNMV).

Data summarised monthly by Lightyear AI. Last updated on 16 Jun 2026.

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Market data provided by CBOE Europe and Deutsche Börse.

About Pharma Mar S.A.

Ticker

Primary listing

Employees

Pharma Mar S.A. Metrics

Price and volume

Financial strength

Profitability

Management effectiveness

Valuation

Growth

Bulls say / Bears say

Buy €PHM

Lightyear

Legal

Work with us

Bulls say / Bears say

Pharma Mar S.A./€PHM

About Pharma Mar S.A.

Ticker

Primary listing

Employees

Pharma Mar S.A. Metrics

Price and volume

Financial strength

Profitability

Management effectiveness

Valuation

Growth

Bulls say / Bears say

What’s the current market cap for Pharma Mar S.A. stock?

What is the P/E ratio for Pharma Mar S.A. stock?

Does Pharma Mar S.A. stock pay dividends?

When is the next Pharma Mar S.A. dividend payment date?

What is the beta indicator for Pharma Mar S.A.?

Bulls say / Bears say